

# **PRISM MEDICO AND PHARMACY LIMITED**

CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com  
Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030.

Date: 21.11.2025

To,  Department of Corporate Services, <b>BSE LIMITED</b> P. J. Towers, Dalal Street, Mumbai, Maharashtra-400 001  <b>ISIN : INE730E01016</b> <b>Scrip Code: 512217</b>	To,  Listing Department, <b>Metropolitan Stock Exchange of India Limited</b> <b>(MSEI)</b> Vibgyor Towers, 4 <sup>th</sup> Floor, Plot Number C 62, G - Block, Opposite Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai, Maharashtra-400098. <b>SYMBOL: PRISMMEDI</b>
---	---

**Subject: Clarification with respect to outcome of the Board Meeting held on 14<sup>th</sup> November, 2025.**

**Dear Sir/Madam,**


This has the reference of email dated 21<sup>st</sup> November, 2025 received from your good office on the captioned subject. In this regard it is hereby clarified that the company has submitted the outcome of Board Meeting held on 14<sup>th</sup> November, 2025 along with the financial results in Pdf and XBRL format with BSE and MSEI within the prescribed time. However, inadvertently the scanned file of "Statement of Asset and Liabilities" and "Cash Flow Statement" could not be uploaded with the Pdf file of the outcome filed with the stock exchanges. Whereas, all the requisite data was provided in the XBRL file uploaded on the portal of the stock exchanges.

In view of the above and to make good the inadvertent and unintentional error the pdf file of the outcome is being uploaded again on the portal of the stock exchanges.

Kindly take on record the same and oblige.

Thanking You.

Yours Truly,  
**FOR PRISM MEDICO AND PHARMACY LIMITED**

  
**DAVENDER SINGH**  
**DIRECTOR**  
**DIN: 09447213**

# **PRISM MEDICO AND PHARMACY LIMITED**

CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com  
Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030

Date: 14.11.2025

To,  Department of Corporate Services, <b>BSE LIMITED</b> P. J. Towers, Dalal Street, Mumbai, Maharashtra-400001.  <b>ISIN : INE730E01016</b> <b>Scrip Code: 512217</b>	To,  Listing Department, <b>Metropolitan Stock Exchange of India Limited</b> <b>(MSEI)</b> Vibgyor Towers, 4 <sup>th</sup> Floor, Plot Number C 62, G - Block, Opposite Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai, Maharashtra-400098. <b>SYMBOL: PRISMEDI</b>
---	--

**Subject: Outcome of the Board Meeting - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,


Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today (i.e. 14<sup>th</sup> November, 2025) which commenced at 03:30 P.M. and concluded at 06:00 P.M. have inter alia approved the following:

- The Board considered and approved the Unaudited Standalone Financial Results of the company for the quarter and half year ended 30<sup>th</sup> September, 2025 alongwith the Limited Review Report duly signed by the Auditors of the company.

You are requested to kindly take the same on record and oblige.

Thanking You.

Yours Truly,  
**FOR PRISM MEDICO AND PHARMACY LIMITED**



**DAVENDER SINGH**  
**DIRECTOR**  
**DIN: 09447213**



**Limited Review Report on Standalone Financial Results**

To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Standalone Un-Audited Financial Result of **\*M/s. Prism Medico And Pharmacy Ltd\*** having its Regd. Office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh – 173030 for the **Quarter ended 30th September 2025** ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements). Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **GARG MENDIRATTA & ASSOCIATES.**  
**CHARTERED ACCOUNTANTS.**



**CA JASPREET SINGH MENDIRATTA**  
M. No 097687  
Date: 14.11.2025  
UDIN : 25097687BMHIMY1109

## PRISM MEDICO AND PHARMACY LIMITED

CIN: L24100HP2002PLCO09299; EMAIL ID: INVESTORGRIEVANCEWML@gmail.com

REGISTERED OFFICE: SUKETI ROAD, KALA AMB, SIRMAUR, HIMACHAL PRADESH-173030

### STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025 (In Lakhs)

PARTICULARS	Quarter Ended			Year to date 30.09.2025	Year Ended (Audited)	Year Ended (Audited)
	30.09.2025	30.06.2025	30.09.2024		31.03.2025	31.03.2024
<b>I Income</b>						
Revenue from operations	50.23	158.87	28.78	209.10	63.19	292.52
Other income	1.67	0.04	-	1.71	1.65	12.22
<b>Total income from operations</b>	<b>51.90</b>	<b>158.91</b>	<b>28.78</b>	<b>210.81</b>	<b>64.84</b>	<b>304.74</b>
<b>II Expenses</b>						
Cost of material consumed	45.35	85.75	23.68	131.10	44.85	256.08
Change in inventories	-	-	-	-	-	-
Employee benefit expenses	1.20	0.95	1.03	2.15	4.26	3.40
Finance costs	0.28	-	-	0.28	0.17	0.71
Depreciation and amortization expenses	0.10	0.13	0.13	0.23	0.42	0.53
Other expenses	13.45	7.01	2.94	20.46	21.72	46.81
<b>Total expenses</b>	<b>60.38</b>	<b>93.84</b>	<b>27.78</b>	<b>154.22</b>	<b>71.42</b>	<b>307.53</b>
<b>III Profit/(Loss) before exceptional items and tax</b>	<b>(8.48)</b>	<b>65.07</b>	<b>1.00</b>	<b>56.59</b>	<b>(6.58)</b>	<b>(2.79)</b>
<b>IV Exceptional items</b>	-	-	-	-	-	-
<b>V Profit/(Loss) before tax</b>	<b>(8.48)</b>	<b>65.07</b>	<b>1.00</b>	<b>56.59</b>	<b>(6.58)</b>	<b>(2.79)</b>
<b>VI Tax expenses</b>						
a) Current tax	-	-	-	-	-	-
b) Deferred tax	-	0.66	(0.06)	0.66	1.71	0.66
b) Mat Credit	-	-	-	-	-	-
<b>VII Net Profit/(Loss) for the period/year</b>	<b>(8.48)</b>	<b>65.73</b>	<b>0.94</b>	<b>57.25</b>	<b>(4.87)</b>	<b>(2.13)</b>
<b>VIII Other comprehensive income (net of tax)</b>						
<b>Items that will not be reclassified to profit or loss:</b>						
i) Remeasurement of post employment benefit obligations	-	-	-	-	-	-
ii) Prior period income adjustment (Net of tax)	-	-	-	-	-	0.12
<b>Total other comprehensive income</b>	-	-	-	-	-	<b>0</b>
<b>IX Total comprehensive income for the period/year (VII+VIII)</b>	<b>(8.48)</b>	<b>65.73</b>	<b>0.94</b>	<b>57.25</b>	<b>(4.87)</b>	<b>(2.01)</b>
<b>X Paid-up equity share capital (face value of the share shall be indicated)</b>	<b>606.34</b>	<b>606.34</b>	<b>606.34</b>	<b>606.34</b>	<b>606.34</b>	<b>606.34</b>
<b>XI Other equity (excluding revaluation reserve)</b>	<b>960.19</b>	<b>968.67</b>	<b>899.75</b>	<b>960.19</b>	<b>902.94</b>	<b>907.81</b>
<b>XII EPS in Rs. (Face Value of Rs.10/- each)*</b>						
- Basic	(0.0014)	0.0108	0.0002	0.0094	(0.0008)	(0.0004)
- Diluted	(0.0014)	0.0108	0.0002	0.0094	(0.0008)	(0.0004)

**Notes:**

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 14.11.2025 after being reviewed by the Audit Committee.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The company is having single segment in accordance with IND AS 108 "Operating Segments" and therefore segment reporting is not applicable to the company.

**FOR AND ON BEHALF OF THE BOARD  
PRISM MEDICO AND PHARMACY LIMITED**




**DAVENDER SINGH  
DIRECTOR  
DIN: 09447213**

Place: KALA AMB, HIMACHAL PRADESH.  
Date: 14TH NOVEMBER, 2025.

**Prism Medico and Pharmacy Limited**  
**Statement of Assets and Liabilities**  
**For the half year ended on 30th September, 2025**

	(Rs. In Lakhs)	(Rs. In Lakhs)
PARTICULARS	30TH SEPTEMBER, 2025	31ST MARCH, 2025
<b>I. ASSETS</b>		
(1) Non - Current Assets		
(a) Property, Plant and Equipment	2.70	2.93
b) Financial Assets	-	-
(1) Non-Current Investments	-	-
b) Deffered Tax Asset	24.35	23.69
	-	-
(2) Current Assets	-	-
(a) Inventories	677.06	677.06
b) Financial Assets	-	-
(1) Cash and Cash Equivalent	45.33	6.54
(2) Short Term Loans and advances	352.56	351.12
(3) Trade Receivables	366.76	358.42
(c) Other Current Asset	114.59	136.69
	<b>1,583.36</b>	<b>1,556.45</b>
<b>II. EQUITY AND LIABILITIES</b>		
(1) Equity		
(a) Equity Share Capital	606.34	606.34
(b) Other Equity	960.19	902.94
	-	-
(2) Current Liabilities	-	-
a) Financial Liabilities	-	-
(1) Trade Payables	14.56	-
(b) Other Current Liabilities	2.27	47.17
	<b>1,583.36</b>	<b>1,556.45</b>


FOR AND ON BEHALF OF THE BOARD  
PRISM MEDICO AND PHARMACY LIMITED

  
**DAVENDER SINGH**  
DIRECTOR  
DIN: 09447213

Place: KALA AMB, HIMACHAL PRADESH.  
Date: 14TH NOVEMBER, 2025.

PRISM MEDICO AND PHARMACY LIMITED			
Cash Flow Statement for the half year ended 30th September, 2025			
		(Rs. In Lakhs)	(Rs. In Lakhs)
	Particulars	Year ended 30th September, 2025 Amount	Year ended 31st March, 2025 Amount
A.	<b>Cash Flow from Operating Activities:</b>		
	Profit before tax for the year	56.59	(6.58)
	Adjustments for :	-	-
	Depreciation & Amortization	0.23	0.42
	Change in reserves	-	-
	Interest and Finance Charges	0.28	0.17
		-	-
	<b>Operating Profit Before Prior Period Items and Working Capital Change</b>	<b>57.10</b>	<b>(5.99)</b>
		-	-
	<b>Operating Profit Before Working Capital Changes</b>	<b>57.10</b>	<b>(5.99)</b>
	Adjustments for:	-	-
	Decrease/ (Increase) in Receivables	(8.34)	10.55
	Inventories	-	-
	Other Current Assets	20.66	(43.40)
	Other Current Liabilities	(44.90)	40.09
	Increase/ (Decrease) in Trade Payables	14.56	(3.08)
		-	-
	<b>Cash Generated from Operations</b>	<b>39.07</b>	<b>(1.83)</b>
	Income Tax Paid	-	0.18
	<b>Net Cash from Operating Activities</b>	<b>39.07</b>	<b>(1.65)</b>
		-	-
B.	<b>Cash Flow from Investing Activities:</b>		
	Investments sold	-	-
	Change in Loans and Advances	-	-
		-	-
	<b>Net Cash (used)/Generated in Investing Activities</b>	<b>-</b>	<b>-</b>
		-	-
C.	<b>Cash Flow from Financing Activities:</b>		
	Interest and Other Finance Costs paid	(0.28)	(0.17)
		-	-
	<b>Net Cash (Used)/Generated in Financing Activities</b>	<b>(0.28)</b>	<b>(0.17)</b>
		-	-
	<b>Net Increase in Cash and Cash Equivalents (A)+(B)+( C)</b>	<b>38.79</b>	<b>(1.82)</b>
	Opening Cash and Cash Equivalents	6.54	8.36
	Closing Cash and Cash Equivalents	45.33	6.54

FOR AND ON BEHALF OF THE BOARD  
PRISM MEDICO AND PHARMACY LIMITED



DAVENDER SINGH  
DIRECTOR  
DIN: 09447213

Place: KALA AMB, HIMACHAL PRADESH.  
Date: 14TH NOVEMBER, 2025.

# **PRISM MEDICO AND PHARMACY LIMITED**

CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com

Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030

**TEXT OF RESOLUTION PASSED AT A DULY CONVENED MEETING OF THE BOARD OF DIRECTORS OF THE COMPANY HELD DURING THE FINANCIAL YEAR 2025-2026 ON FRIDAY, THE 14<sup>TH</sup> DAY OF NOVEMBER, 2025 AT 03:30 P.M. AT THE REGISTERED OFFICE OF THE COMPANY SITUATED AT SUKETI ROAD, KALA AMB, SIRMAUR, HIMACHAL PRADESH-173030.**

**2. TO APPROVE THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER, 2025.**

The Board discussed and then passed the following resolution:

**"RESOLVED THAT** pursuant to the applicable provisions of the Companies Act, 2013 and Rules made thereunder (including any statutory modification or re-enactment(s) thereof for the time being in force) and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 the unaudited standalone financial results of the company for the quarter and half year ended 30<sup>th</sup> September, 2025 as reviewed by the Audit Committee and tabled before the Board be and hereby approved."

**"RESOLVED FURTHER THAT** Mr. Davender Singh, Director of the company be and is hereby authorized to sign the said statement of accounts and to do all such acts, deeds, and things as may be necessary to give effect to the above said resolution."

**CERTIFIED TO BE TRUE COPY  
FOR PRISM MEDICO AND PHARMACY LIMITED**



**DAVENDER SINGH  
DIRECTOR (DIN: 09447213)  
VILLAGE DHALOUR, P.O. SHERPUR,  
SALKHANI, SARAWAN, YAMUNANAGAR,  
HARYANA-133206.**